---
schema_version: "secwatch.filing_event.v1"
accession: "0001773751-25-000352"
form_type: "8-K"
ticker: "HIMS"
cik: "0001773751"
company_name: "Hims & Hers Health, Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:55:17.772060+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Hims & Hers Q3 revenue $599M (+49% YoY), Adj. EBITDA $78.4M; narrows FY25 guidance

## Summary
- Q3 revenue $599M (+49% YoY), net income $15.8M (prior-year $75.6M included $60.8M tax benefit)
- Adj. EBITDA $78.4M (+53% YoY); subscribers 2.47M (+21% YoY); monthly online revenue per subscriber $80 (+19% YoY)
- Gross margin 74% vs 79% YoY, hit by shorter shipping cadences for weight-loss offerings
- FY25 revenue guidance narrowed to $2.34-2.36B, Adj. EBITDA guidance $307-317M
- Entering testosterone, menopause care; discussions with Novo Nordisk for Wegovy; GRAIL investment

## SEC filing metadata
- accession: 0001773751-25-000352
- form_type: 8-K
- ticker: HIMS
- cik: 0001773751
- company_name: Hims & Hers Health, Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1773751/000177375125000352/0001773751-25-000352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1773751/000177375125000352/hims-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001773751-25-000352
- JSON: https://secwatch.observer/filing/0001773751-25-000352.json
- Plain text: https://secwatch.observer/filing/0001773751-25-000352.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.